NCT00104455View on ClinicalTrials.gov

Dose Response to Recombinant Factor VIIa When Administered for Bleed

PHASE1CompletedINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

November 30, 2004

Study Completion Date

November 30, 2004

Conditions

Congenital Bleeding DisorderHealthy

Interventions

DRUG

activated recombinant human factor VII

Trial Locations (1)

66211

Novo Nordisk Investigational Site, Overland Park

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY